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ABSTRACT 51 
 52 
Recent studies have revealed that newly emerging transformed cells are often 53 
apically extruded from epithelial tissues. During this process, normal epithelial 54 
cells can recognize and actively eliminate transformed cells, a process called 55 
Epithelial Defence Against Cancer (EDAC). Here, we show that mitochondrial 56 
membrane potential is diminished in RasV12-transformed cells when they are 57 
surrounded by normal cells. In addition, glucose-uptake is elevated, leading to 58 
higher lactate production. The mitochondrial dysfunction is driven by 59 
upregulation of pyruvate dehydrogenase kinase 4, which positively regulates 60 
elimination of RasV12-transformed cells. Furthermore, EDAC from the 61 
surrounding normal cells, involving Filamin, drives the Warburg effect-like 62 
metabolic alteration. Moreover, using a cell competition mouse model, we 63 
demonstrate that PDK-mediated metabolic changes promote the elimination of 64 
RasV12-transformed cells from intestinal epithelia. These data indicate that non-65 
cell-autonomous metabolic modulation is a crucial regulator for cell competition, 66 
shedding light on the unexplored events at the initial stage of carcinogenesis. 67 
68 
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INTRODUCTION 69 
 70 
It remains enigmatic what happens at the initial stage of carcinogenesis where 71 
oncogenic transformation occurs in a single cell within the epithelium1-3. Recent 72 
studies have demonstrated that newly emerging transformed cells are often eliminated 73 
from epithelial tissues via cell competition against the neighbouring normal epithelial 74 
cells. Cell competition is a process by which two different cell populations, upon 75 
interaction, compete with each other for survival and space; consequently, the loser 76 
cells are eliminated from the tissues, while the winner cells occupy the vacant spaces. 77 
This phenomenon was originally found and has been extensively studied in 78 
Drosophila4-9. But, recent studies have revealed that cell competition can also occur in 79 
mammals between normal and various types of transformed epithelial cells. For 80 
example, RasV12-, Src- or erbB2-transformed cells are apically extruded when they 81 
are surrounded by normal epithelial cells10-13. In addition, tumour suppressor protein 82 
Scribble- or Mahjong-knockdown cells undergo apoptosis and leave a monolayer of 83 
normal epithelial cells7, 14. Importantly, when transformed cells alone are present, 84 
neither apical extrusion nor apoptosis occurs, indicating that the presence of the 85 
surrounding normal cells profoundly influences the behaviour and fate of transformed 86 
cells.  87 
We and other groups have explored the molecular mechanisms of cell competition 88 
between normal and RasV12-transformed epithelial cells and revealed that various 89 
non-cell-autonomous changes occur in both cells at their interface. For instance, 90 
normal epithelial cells accumulate cytoskeletal protein Filamin at the interface with 91 
the adjacent transformed cells, thereby actively eliminating them15. This implies a 92 
notion that normal epithelial cells have anti-tumour activity that does not involve 93 
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immune cells: a process termed EDAC (Epithelial Defence Against Cancer)15. By 94 
contrast, in RasV12-transformed cells that are surrounded by normal cells, actin-95 
binding protein Epithelial Protein Lost In Neoplasm (EPLIN) is accumulated16. The 96 
accumulated EPLIN then activates the downstream molecules such as PKA and 97 
myosin-II, which positively regulate apical extrusion of RasV12 cells. However, the 98 
molecular mechanisms of how EDAC from normal cells affects the neighbouring 99 
transformed cells and promotes their elimination are still poorly understood.  100 
Cellular metabolism is dynamically modulated and adjusted in accordance with 101 
various conditions. For example, at the later stage of cancer development, aerobic 102 
glycolysis is enhanced in tumour cells, often accompanied by the downregulation of 103 
mitochondrial activity; these metabolic changes are called Warburg effect17-21. But, it 104 
is not clearly understood whether cellular metabolism is also affected at the initial 105 
stage of carcinogenesis. In this study, we have examined whether and how the 106 
metabolic status is regulated at the interface between normal and newly emerging 107 
transformed epithelial cells. 108 
109 
 6
RESULTS 110 
Warburg effect-like metabolic changes occur in RasV12-transformed cells that 111 
are surrounded by normal cells  112 
To examine the involvement of metabolic regulation in cell competition, we first 113 
examined mitochondrial energy metabolism at the interface between normal and 114 
RasV12-transformed epithelial cells. TMRM (tetramethylrhodamine methyl ester) is a 115 
positively charged red fluorescent dye that accumulates in active mitochondria 116 
according to the negative membrane potential gradient across their inner membranes. 117 
We found that the TMRM fluorescence, but not the fluorescence of a control dye 118 
CMTPX, was strongly reduced in RasV12-transformed epithelial cells surrounded by 119 
normal epithelial cells compared to that in RasV12-transformed cells cultured alone 120 
or in GFP-expressing cells surrounded by normal cells (Fig. 1a-c, g). The comparable 121 
phenomenon was also observed in Src-transformed cells, but not in Scribble-122 
knockdown cells (Supplementary Fig. 1a, b). The decreased incorporation of TMRM 123 
was observed in both apically extruding and extruded RasV12 cells (Fig. 1d). The mix 124 
ratio of normal and RasV12 cells affected the TMRM incorporation in RasV12 cells; 125 
the decreased TMRM incorporation was clearly observed at 50:1 or 10:1, but less 126 
frequently occurred at 4:1 or 1:1. This is compatible with the previous report 127 
demonstrating that the proportion of winner-loser cells profoundly influences the 128 
occurrence of cell competition22. The non-cell-autonomous downregulation of 129 
mitochondrial membrane potential was also confirmed by using mitoSOX, an 130 
indicator for mitochondrial superoxide production that reflects mitochondrial ATP 131 
production (Fig. 1e-g). Immunofluorescence of the mitochondrial resident protein 132 
Tom20 or MitoTracker Green fluorescence which is incorporated into mitochondria in 133 
a membrane potential-independent manner showed that the number of mitochondria 134 
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was not altered in RasV12 cells surrounded by normal cells (Fig. 1h and 135 
Supplementary Fig. 1c-h). In addition, by electron microscopic analyses, 136 
mitophagosome-like structures were frequently observed in RasV12 cells that were 137 
surrounded by normal epithelial cells (Supplementary Fig. 2). Collectively, these data 138 
imply that the decreased TMRM incorporation does not result from a change in 139 
mitochondrial mass, but from a change in mitochondrial function. Furthermore, we 140 
found that incorporation of glucose analogue 2-NBDG was enhanced in RasV12 cells 141 
surrounded by normal cells (Fig. 2a, b), suggesting that uptake of glucose is enhanced 142 
in a non-cell-autonomous fashion. Moreover, expression of LDHA, which converts 143 
pyruvate to lactate, was significantly increased in RasV12-transformed cells that were 144 
surrounded by normal cells (Fig. 2c-e and Supplementary Fig. 3a). Accordingly, 145 
lactate secretion was higher in RasV12 cells than normal cells, and was further 146 
enhanced when RasV12 cells were surrounded by normal cells (Fig. 2f). This non-147 
cell-autonomous increase in lactate secretion was abolished when LDHA was 148 
knocked down in RasV12 cells (Fig. 2f and Supplementary Fig. 4e). These data 149 
indicate that the interaction with the neighbouring normal epithelial cells potentiates 150 
the Warburg effect-like metabolic changes in transformed cells: downregulation of 151 
mitochondrial function and enhanced aerobic glycolysis. 152 
 153 
PDK4 plays a crucial role in the decreased mitochondrial membrane potential 154 
and apical extrusion of RasV12-transformed cells surrounded by normal cells 155 
To reveal the molecular mechanism that causes the Warburg effect-like phenomenon, 156 
we examined expression of various metabolic enzymes by quantitative real-time PCR 157 
and found that expression of pyruvate dehydrogenase kinase 4 (PDK4) was 158 
significantly elevated in RasV12-transformed cells when they were co-cultured with 159 
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normal cells (Fig. 3a). PDK4 phosphorylates and thus inactivates pyruvate 160 
dehydrogenase (PDH) that catalyses conversion of pyruvate to acetyl-CoA, thereby 161 
blocking the entry into the TCA cycle (Supplementary Fig. 3a). Indeed, 162 
phosphorylation of PDH was also enhanced in RasV12 cells when they were 163 
surrounded by normal cells (Fig. 3b-d). To examine the functional involvement of 164 
PDK4, we established RasV12-transformed cells stably expressing PDK4-shRNA 165 
(Fig. 3e) and CRISPR-edited PDK4-knockout RasV12-transformed cells 166 
(Supplementary Fig. 3b). PDK4-knockdown or PDK4-knockout suppressed PDH 167 
phosphorylation and significantly restored TMRM incorporation in RasV12 cells 168 
surrounded by normal cells (Fig. 3f, g and Supplementary Fig. 3c-g), suggesting that 169 
upregulation of PDK4 is, at least partly, responsible for the decreased mitochondrial 170 
membrane potential. PDK4-knockdown or -knockout also suppressed LDHA 171 
accumulation (Supplementary Fig. 3h-j). Interestingly, PDK4-knockdown or -172 
knockout drastically suppressed apical extrusion of RasV12 cells, while promoting 173 
formation of basal protrusions that extended beneath the neighbouring normal cells 174 
(Fig. 3h, i and Supplementary Fig. 3k-n). DCA is a specific inhibitor of the PDK 175 
family23, 24 of which upregulation is often observed in the later stage of cancer25-28. 176 
Therefore, DCA has been intensively tested in clinical trials for treatment of 177 
malignant cancer including glioblastoma and various solid tumours29-32. We found 178 
that treatment of DCA caused the comparable effect to that induced by PDK4 179 
knockdown/knockout: suppression of PDH phosphorylation (Fig. 4a), restoration of 180 
TMRM incorporation (Fig. 4b, c) and suppression of apical extrusion and promotion 181 
of basal protrusions (Fig. 4d, e). We also demonstrated that another PDK inhibitor 182 
Radicicol phenocopied the effect of DCA (Supplementary Fig. 4a-d). DCA treatment 183 
also suppressed elevated LDHA expression in RasV12 cells surrounded by normal 184 
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cells (Fig. 4a). In contrast, knockdown of LDHA in RasV12 cells did not affect 185 
TMRM incorporation (Supplementary Fig. 4e, f), suggesting that decreased 186 
mitochondrial membrane potential causes LDHA upregulation. Moreover, 187 
knockdown of LDHA moderately suppressed apical extrusion (Supplementary Fig. 188 
4g). These results imply that the PDK4-mediated Warburg effect-like metabolic 189 
alteration influences the behaviour of transformed cells and promotes their 190 
elimination from epithelia. When PDH-knockdown cells were surrounded by normal 191 
cells, apical extrusion did not occur (Supplementary Fig. 4h-j), indicating that 192 
downregulation of mitochondrial membrane potential alone is not sufficient to cause 193 
apical extrusion. Thus, while the non-cell-autonomously induced metabolic changes 194 
play an indispensable role in the elimination of transformed cells, additional, 195 
unidentified molecular mechanisms are also involved in this process, which need to 196 
be explored in future studies. 197 
 198 
EDAC and EPLIN act upstream of the Warburg effect-like metabolic changes in 199 
RasV12 cells surrounded by normal cells 200 
We further examined the molecular mechanism underlying the Warburg effect-like 201 
phenomenon. In a previous study, we demonstrated that EPLIN accumulates in 202 
RasV12-transformed cells surrounded by normal cells and plays a positive role in the 203 
apical extrusion via activation of the downstream molecules, protein kinase A (PKA) 204 
and myosin-II16. We found that knockdown of EPLIN in RasV12 cells significantly 205 
restored mitochondrial membrane potential (Fig. 5a, b and Supplementary Fig. 5a). In 206 
addition, EPLIN-knockdown suppressed PDK4 upregulation, phosphorylation of 207 
PDH and LDHA accumulation (Fig. 5c, d and Supplementary Fig. 5b). These data 208 
indicate that EPLIN is a crucial upstream regulator of the Warburg effect-like 209 
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metabolic changes. Furthermore, we examined the effect of various inhibitors on 210 
TMRM incorporation and apical extrusion. Concerning downstream molecules of 211 
EPLIN, PKA inhibitor KT5720 reverted TMRM incorporation, whereas myosin-II 212 
inhibitor Blebbistatin did not (Supplementary Fig. 5c and Supplementary Fig. 8a). 213 
The other tested inhibitors (Cytochalasin D, NAC, 3-MA, Y27632, L-NAME) did not 214 
affect TMRM incorporation (Supplementary Fig. 5c and Supplementary Fig. 8a), 215 
indicating the specific effect of KT5720 on TMRM incorporation. Furthermore, 216 
KT5720 did not significantly affect expression of PDK4. These data suggest that 217 
EPLIN regulates those metabolic changes via PDK4- and PKA-dependent pathways 218 
(Supplementary Fig. 8c).  219 
It was previously reported that normal epithelial cells can recognize and actively 220 
eliminate the neighbouring transformed cells, in which Filamin in the normal cells 221 
plays an important role, at least partly, by inducing the accumulation of EPLIN in 222 
transformed cells15, 16; this tumour-suppressing process is called EDAC15. When 223 
RasV12 cells were surrounded by EDAC-deficient Filamin-knockdown cells, TMRM 224 
incorporation in RasV12 cells was restored, instead rather promoted in comparison to 225 
that in the surrounding knockdown cells (Fig. 5e, f and Supplementary Fig. 3f and 226 
5a). In addition, knockdown of Filamin in the surrounding normal cells substantially 227 
suppressed phosphorylation of PDH and accumulation of LDHA (Fig. 5g and 228 
Supplementary Fig. 3d, i and 5b). Collectively, these data demonstrate that EDAC 229 
from normal cells induces the metabolic alterations of the neighbouring transformed 230 
cells via EPLIN, thereby promoting elimination of the transformed cells from 231 
epithelia (Supplementary Fig. 8c).  232 
 233 
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Upregulation of the glycolytic pathway plays a positive role in the elimination of 234 
RasV12-transformed cells 235 
What is the functional significance of EDAC-induced Warburg effect-like metabolic 236 
changes in the apical elimination of transformed cells? The metabolic shift from 237 
mitochondrial oxidative phosphorylation to glycolysis can affect various cellular 238 
processes such as glucose metabolism, ATP production and resistance to ROS-239 
mediated oxidative stress. Using a glucose-FRET probe, we found that intracellular 240 
glucose concentration was substantially diminished in RasV12 cells surrounded by 241 
normal cells (Fig. 6a-c), indicating that intracellular glucose is exhausted via 242 
massively elevated glycolysis despite of the increased glucose uptake (Fig. 2a, b). The 243 
comparable glucose metabolic condition is also reported in conventional Warburg 244 
effect33-35. In addition, the result with the FRET-based ATP sensor (ATeam) showed 245 
that the ATP level was moderately increased in RasV12-transformed cells that were 246 
surrounded by normal cells (Supplementary Fig. 5d-f), suggesting that the ATP 247 
production is fully compensated and even promoted by the enhanced glycolytic 248 
pathway. To further understand the functional significance of this process, we 249 
examined the effect of a hexokinase inhibitor 2-deoxy-D-glucose (2-DG). Addition of 250 
2-DG diminished the non-cell-autonomously upregulated ATP level (Supplementary 251 
Fig. 5e-g) and significantly suppressed apical extrusion of RasV12 cells surrounded 252 
by normal cells (Supplementary Fig. 5h, i), indicating that the upregulation of the 253 
glycolytic pathway plays a positive role in the elimination of transformed cells. The 254 
ATP production speed via glycolysis is far greater than that via mitochondria36, hence 255 
the metabolic shift to glycolysis may be of benefit to transformed cells by supporting 256 
prompt energy supply required for the dynamic process of apical extrusion. Note that 257 
2-DG could inhibit both oxidative and fermentative glucose metabolism. To further 258 
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clarify the metabolic alterations during apical extrusion, additional experiments are 259 
required in future studies. 260 
 261 
PDK-mediated mitochondrial dysfunction induces apical elimination of RasV12-262 
transformed cells ex vivo and in vivo 263 
To understand the generality and functional significance of these findings, we 264 
established an LSL-RasV12-IRES-eGFP mouse whereby RasV12 expression is 265 
induced in a Cre-dependent fashion and traced by simultaneous expression of eGFP 266 
(Supplementary Fig. 6a, b). By crossing a Villin-Cre-ERT2 mouse with an LSL-267 
RasV12-IRES-eGFP mouse, we obtained a cell competition mouse model (Fig. 7a). 268 
Administration of a low dose of tamoxifen induces recombination events less 269 
frequently, resulting in expression of RasV12 in a mosaic manner within intestinal 270 
epithelia (Supplementary Fig. 6c). Using this system, we examined the fate of newly 271 
emerging RasV12-transformed cells that are surrounded by normal epithelial cells ex 272 
vivo and in vivo. First, intestinal epithelial cells were collected from these mice and 273 
were subjected to crypt organoid culture in the matrigel, followed by tamoxifen 274 
treatment37. At 12-24 h after treatment with a low dose of tamoxifen, RasV12-275 
expressing cells were apically shifted with wedge-like morphology; at 36-48 h, 276 
RasV12 cells were detached from the basement membrane and eventually extruded 277 
into the apical lumen (Fig. 7b, top). In contrast, cells expressing only GFP remained 278 
within the epithelium, and apical extrusion did not frequently occur (Fig. 7b, bottom). 279 
When RasV12 were predominantly expressed in the whole epithelium by a high dose 280 
of tamoxifen, the frequency of apical extrusion was strongly suppressed (Fig. 7c), 281 
indicating that the presence of the surrounding normal cells induced the elimination of 282 
transformed cells in the ex vivo system as well. We also found that EPLIN was 283 
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accumulated in RasV12 cells surrounded by normal cells in a non-cell-autonomous 284 
fashion (Supplementary Fig. 7a). Time-lapse analyses of the crypt organoid culture 285 
revealed that the event of apical extrusion took rather variable times between 2-20 h 286 
and that the extruded transformed cells disappeared into the apical lumen 287 
(Supplementary Fig. 7b and Supplementary Videos 1-3). Thus, we have successfully 288 
established a mouse model system, in which apical elimination of RasV12-289 
transformed cells can be captured three-dimensionally. Using this experimental 290 
system, we found that TMRM incorporation was diminished in both extruding and 291 
extruded RasV12-expressing cells that were surrounded by normal cells (Fig. 7d, first 292 
and second upper panels, e), but not in RasV12-expressing cells surrounded by 293 
themselves or in GFP-expressing cells (Fig. 7d, third and fourth panels, e). In 294 
addition, phosphorylation of PDH was elevated in RasV12 cells surrounded by 295 
normal cells (Fig. 7f). Furthermore, DCA treatment restored the TMRM incorporation 296 
and suppressed the apical extrusion of RasV12 cells (Fig. 7g, h and Supplementary 297 
Fig. 7c, d). Finally, we examined the fate of RasV12-transformed cells in vivo. 298 
Intraperitoneal injection of a low dose of tamoxifen induced RasV12 expression in a 299 
mosaic manner within the intestinal epithelium, and most of RasV12-expressing cells 300 
were apically eliminated after three days of tamoxifen treatment, whereas GFP-301 
expressing cells remained in the epithelial layer (Fig. 8a-c). Using two-photon 302 
microscopic in vivo time-lapse imaging, the dynamic mode of apical extrusion of 303 
RasV12-expressing cells was captured (Fig. 8d and Supplementary Video 4). Finally, 304 
we examined the functional role of PDK in the elimination of RasV12 cells from 305 
epithelia in vivo. When DCA was administered, apical extrusion of RasV12 cells was 306 
significantly suppressed (Fig. 8e, f). Furthermore, we used the recently established 307 
iGT (intestine-specific gene transfer) system where mouse intestinal epithelia can be 308 
 14
transfected with siRNA using HVJ-E (haemagglutinating virus of Japan envelope) 309 
(Fig. 8g, h)38. We then demonstrated that knockdown of PDK4 significantly 310 
suppressed apical extrusion (Fig. 8i-k). Collectively, these data suggest that apical 311 
elimination of RasV12-transformed cells occurs ex vivo and in vivo, which is 312 
promoted by the PDK4-mediated mitochondrial downregulation. 313 
314 
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Discussion 315 
The glycolytic pathway and mitochondrial function are frequently de-regulated in 316 
neoplastic cells in various ways. These metabolic alterations are generally thought to 317 
promote cancer progression, though its biological and pathological significance still 318 
remains elusive17-20. Indeed, clinical trials targeting derailed mitochondrial 319 
metabolism, such as with DCA, are currently undergoing29-32. By contrast, our study 320 
suggests that the Warburg effect-like metabolic changes can occur at the early stage 321 
of carcinogenesis in a non-cell-autonomous fashion and that DCA treatment could 322 
potentially suppress eradication of newly emerging transformed cells. Thus, the 323 
adverse effect of DCA may need to be carefully re-examined for the longer time 324 
periods.  325 
The EDAC-mediated Warburg effect-like metabolic shift does not accommodate 326 
several features of the prevailing Warburg effect (Supplementary Fig. 8b). 327 
Conventional Warburg effect, which is often observed at the relatively late phase of 328 
cancer progression, is caused by various genetic and epigenetic insults and adaptation 329 
to harsh tumour microenvironments. In contrast, EDAC-induced Warburg effect-like 330 
metabolic changes are triggered by the inputs from neighbouring normal cells at the 331 
initial stage of carcinogenesis. The conventional Warburg effect is generally 332 
associated with upregulation of HIF1, PDK1/3 and PKM239-46, whereas in EDAC-333 
induced Warburg effect-like metabolic changes the expression of these enzymes is not 334 
elevated, instead EPLIN and PDK4 act as key upstream regulators. Moreover, the 335 
most crucial difference between conventional Warburg effect and EDAC-induced 336 
metabolic changes is their roles in tumourigenesis; the former generally plays a 337 
tumour-promoting role, whereas the latter potentially plays a tumour-suppressive role 338 
by actively eliminating transformed cells. Thus, though these two processes share 339 
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similar metabolic alterations (mitochondrial downregulation and increased aerobic 340 
glycolysis), they are governed by distinct upstream and downstream mediators. 341 
HIF1 is a crucial regulator for Warburg effect by modulating multiple metabolic 342 
pathways including the TCA cycle and glycolytic pathway47. Therefore, we explored 343 
the involvement of HIF1 in EDAC-induced Warburg effect-like metabolic changes. 344 
By using the 5xHRE (HIF1 responsive element) reporter assay, we found that HIF1 345 
activity was not enhanced in RasV12 cells surrounded by normal cells, compared with 346 
that in RasV12 cells cultured alone (Supplementary Fig. 7e). It has been reported that 347 
HIF1 enhances transcription of PDK1/3 and LDHA, thereby inducing Warburg 348 
effect47. But, qRT-PCR analysis demonstrated that the mRNA level of PDK1/3 or 349 
LDHA was not increased in RasV12 cells surrounded by normal cells (Fig. 3a). Thus, 350 
we could not obtain evidence showing the involvement of HIF1 in EDAC-induced 351 
metabolic changes, and our data suggest that LDHA is post-transcriptionally 352 
upregulated by a HIF1-independent, unknown mechanism. 353 
In this study, we have mainly used fluorescence imaging to demonstrate the non-354 
cell-autonomous changes between normal and transformed epithelial cells. In the 355 
research field of cell competition, the researchers have struggled with the technical 356 
problem: biochemical analyses of each cell population in co-cultures. The non-cell-357 
autonomous changes induced by the neighbouring normal cells are regulated 358 
temporally and dynamically, thus once the interaction with normal cells is disrupted, 359 
the non-cell-autonomous biochemical changes (not the mRNA level) will instantly 360 
vanish. To perform biochemical analyses for each cell population, the co-cultured 361 
epithelial cells should be first treated with trypsin to disrupt cell-cell adhesions and 362 
dissociate cells from each other, which will be then FACS sorted for a few hours. 363 
Despite of the substantial number of trials, we have found just minor remaining non-364 
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cell-autonomous traces after those procedures. To further intensify the findings in this 365 
study, we need to exploit new methods such as FRET probes for metabolites in future 366 
studies. 367 
A previous study in Drosophila has shown that mitochondrial metabolism can be 368 
regulated during cell competition48. Our data in this study demonstrate that metabolic 369 
modulation is a crucial regulator for cell competition between normal and transformed 370 
epithelial cells in mammals as well. Further elucidation of the molecular mechanisms 371 
that drive the EDAC-induced metabolic changes will lead to novel approaches for 372 
cancer prevention. 373 
 374 
375 
 18
References 376 
1. Hanahan, D. & Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 377 
144, 646-674 (2011). 378 
2. Fialkow, P.J. Clonal origin of human tumors. Biochimica et biophysica acta 379 
458, 283-321 (1976). 380 
3. Nowell, P.C. The clonal evolution of tumor cell populations. Science 194, 23-381 
28 (1976). 382 
4. Morata, G. & Ripoll, P. Minutes: mutants of drosophila autonomously 383 
affecting cell division rate. Dev Biol 42, 211-221 (1975). 384 
5. de la Cova, C., Abril, M., Bellosta, P., Gallant, P. & Johnston, L.A. 385 
Drosophila myc regulates organ size by inducing cell competition. Cell 117, 386 
107-116 (2004). 387 
6. Moreno, E. & Basler, K. dMyc transforms cells into super-competitors. Cell 388 
117, 117-129 (2004). 389 
7. Tamori, Y. et al. Involvement of Lgl and Mahjong/VprBP in cell competition. 390 
PLoS Biol 8, e1000422 (2010). 391 
8. Karim, F.D. & Rubin, G.M. Ectopic expression of activated Ras1 induces 392 
hyperplastic growth and increased cell death in Drosophila imaginal tissues. 393 
Development 125, 1-9 (1998). 394 
9. Brumby, A.M. & Richardson, H.E. scribble mutants cooperate with oncogenic 395 
Ras or Notch to cause neoplastic overgrowth in Drosophila. The EMBO 396 
journal 22, 5769-5779 (2003). 397 
10. Hogan, C. et al. Characterization of the interface between normal and 398 
transformed epithelial cells. Nat Cell Biol 11, 460-467 (2009). 399 
11. Kajita, M. et al. Interaction with surrounding normal epithelial cells influences 400 
signalling pathways and behaviour of Src-transformed cells. J Cell Sci 123, 401 
171-180 (2010). 402 
12. Wu, S.K. et al. Cortical F-actin stabilization generates apical-lateral patterns 403 
of junctional contractility that integrate cells into epithelia. Nat Cell Biol 16, 404 
167-178 (2014). 405 
13. Leung, C.T. & Brugge, J.S. Outgrowth of single oncogene-expressing cells 406 
from suppressive epithelial environments. Nature 482, 410-413 (2012). 407 
14. Norman, M. et al. Loss of Scribble causes cell competition in mammalian 408 
cells. J Cell Sci 125, 59-66 (2012). 409 
15. Kajita, M. et al. Filamin acts as a key regulator in epithelial defence against 410 
transformed cells. Nature communications 5, 4428 (2014). 411 
16. Ohoka, A. et al. EPLIN is a crucial regulator for extrusion of RasV12-412 
transformed cells. J Cell Sci 128, 781-789 (2015). 413 
17. Vander Heiden, M.G., Cantley, L.C. & Thompson, C.B. Understanding the 414 
Warburg effect: the metabolic requirements of cell proliferation. Science 324, 415 
1029-1033 (2009). 416 
18. Sciacovelli, M., Gaude, E., Hilvo, M. & Frezza, C. The metabolic alterations 417 
of cancer cells. Methods in enzymology 542, 1-23 (2014). 418 
19. Koppenol, W.H., Bounds, P.L. & Dang, C.V. Otto Warburg's contributions to 419 
current concepts of cancer metabolism. Nat Rev Cancer 11, 325-337 (2011). 420 
20. Cairns, R.A., Harris, I.S. & Mak, T.W. Regulation of cancer cell metabolism. 421 
Nat Rev Cancer 11, 85-95 (2011). 422 
21. Warburg, O. On the origin of cancer cells. Science 123, 309-314 (1956). 423 
 19
22. Levayer, R., Hauert, B. & Moreno, E. Cell mixing induced by myc is required 424 
for competitive tissue invasion and destruction. Nature 524, 476-480 (2015). 425 
23. Kato, M., Li, J., Chuang, J.L. & Chuang, D.T. Distinct structural mechanisms 426 
for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, 427 
dichloroacetate, and radicicol. Structure 15, 992-1004 (2007). 428 
24. Wynn, R.M. et al. Pyruvate dehydrogenase kinase-4 structures reveal a 429 
metastable open conformation fostering robust core-free basal activity. The 430 
Journal of biological chemistry 283, 25305-25315 (2008). 431 
25. Sutendra, G. et al. Mitochondrial activation by inhibition of PDKII suppresses 432 
HIF1a signaling and angiogenesis in cancer. Oncogene 32, 1638-1650 (2013). 433 
26. Koukourakis, M.I. et al. Pyruvate dehydrogenase and pyruvate dehydrogenase 434 
kinase expression in non small cell lung cancer and tumor-associated stroma. 435 
Neoplasia 7, 1-6 (2005). 436 
27. Hur, H. et al. Expression of pyruvate dehydrogenase kinase-1 in gastric cancer 437 
as a potential therapeutic target. International journal of oncology 42, 44-54 438 
(2013). 439 
28. Lu, C.W. et al. Overexpression of pyruvate dehydrogenase kinase 3 increases 440 
drug resistance and early recurrence in colon cancer. The American journal of 441 
pathology 179, 1405-1414 (2011). 442 
29. Chu, Q.S. et al. A phase I open-labeled, single-arm, dose-escalation, study of 443 
dichloroacetate (DCA) in patients with advanced solid tumors. Investigational 444 
new drugs 33, 603-610 (2015). 445 
30. Dunbar, E.M. et al. Phase 1 trial of dichloroacetate (DCA) in adults with 446 
recurrent malignant brain tumors. Investigational new drugs 32, 452-464 447 
(2014). 448 
31. Strum, S.B. et al. Case report: Sodium dichloroacetate (DCA) inhibition of the 449 
"Warburg Effect" in a human cancer patient: complete response in non-450 
Hodgkin's lymphoma after disease progression with rituximab-CHOP. Journal 451 
of bioenergetics and biomembranes 45, 307-315 (2013). 452 
32. Garon, E.B. et al. Dichloroacetate should be considered with platinum-based 453 
chemotherapy in hypoxic tumors rather than as a single agent in advanced 454 
non-small cell lung cancer. Journal of cancer research and clinical oncology 455 
140, 443-452 (2014). 456 
33. Kami, K. et al. Metabolomic profiling of lung and prostate tumor tissues by 457 
capillary electrophoresis time-of-flight mass spectrometry. Metabolomics : 458 
Official journal of the Metabolomic Society 9, 444-453 (2013). 459 
34. Shestov, A.A. et al. Quantitative determinants of aerobic glycolysis identify 460 
flux through the enzyme GAPDH as a limiting step. eLife 3 (2014). 461 
35. Tang, X. et al. A joint analysis of metabolomics and genetics of breast cancer. 462 
Breast cancer research : BCR 16, 415 (2014). 463 
36. Pfeiffer, T., Schuster, S. & Bonhoeffer, S. Cooperation and competition in the 464 
evolution of ATP-producing pathways. Science 292, 504-507 (2001). 465 
37. Sato, T. et al. Single Lgr5 stem cells build crypt-villus structures in vitro 466 
without a mesenchymal niche. Nature 459, 262-265 (2009). 467 
38. Imajo, M., Ebisuya, M. & Nishida, E. Dual role of YAP and TAZ in renewal 468 
of the intestinal epithelium. Nat Cell Biol 17, 7-19 (2015). 469 
39. Semenza, G.L., Roth, P.H., Fang, H.M. & Wang, G.L. Transcriptional 470 
regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 471 
1. The Journal of biological chemistry 269, 23757-23763 (1994). 472 
 20
40. Gordan, J.D., Thompson, C.B. & Simon, M.C. HIF and c-Myc: sibling rivals 473 
for control of cancer cell metabolism and proliferation. Cancer Cell 12, 108-474 
113 (2007). 475 
41. Kim, J.W., Tchernyshyov, I., Semenza, G.L. & Dang, C.V. HIF-1-mediated 476 
expression of pyruvate dehydrogenase kinase: a metabolic switch required for 477 
cellular adaptation to hypoxia. Cell metabolism 3, 177-185 (2006). 478 
42. Papandreou, I., Cairns, R.A., Fontana, L., Lim, A.L. & Denko, N.C. HIF-1 479 
mediates adaptation to hypoxia by actively downregulating mitochondrial 480 
oxygen consumption. Cell metabolism 3, 187-197 (2006). 481 
43. Kluza, J. et al. Inactivation of the HIF-1alpha/PDK3 signaling axis drives 482 
melanoma toward mitochondrial oxidative metabolism and potentiates the 483 
therapeutic activity of pro-oxidants. Cancer research 72, 5035-5047 (2012). 484 
44. Atsumi, T. et al. High expression of inducible 6-phosphofructo-2-485 
kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. 486 
Cancer research 62, 5881-5887 (2002). 487 
45. Christofk, H.R. et al. The M2 splice isoform of pyruvate kinase is important 488 
for cancer metabolism and tumour growth. Nature 452, 230-233 (2008). 489 
46. Wu, W. & Zhao, S. Metabolic changes in cancer: beyond the Warburg effect. 490 
Acta biochimica et biophysica Sinica 45, 18-26 (2013). 491 
47. Semenza, G.L. HIF-1: upstream and downstream of cancer metabolism. 492 
Current opinion in genetics & development 20, 51-56 (2010). 493 
48. de la Cova, C. et al. Supercompetitor status of Drosophila Myc cells requires 494 
p53 as a fitness sensor to reprogram metabolism and promote viability. Cell 495 
metabolism 19, 470-483 (2014). 496 
 497 
498 
 21
  499 
ACKNOWLEDGEMENTS  500 
We thank K. Rajewsky for the establishment of knocked-in ES cells harbouring 501 
RasV12-eGFP. We also thank H. Harada for the HIF1 reporter-expressing vector, C. 502 
Kuo for the R-spondin-producing cell line and T. Yoshimori for useful advice on EM 503 
analyses. Ya.F. is supported by Japan Society for the Promotion of Science (JSPS) 504 
Grant-in-Aid for Scientific Research on Innovative Areas 26114001, Grant-in-Aid for 505 
Scientific Research (A) 26250026 and AMED Strategic Japanese-Swiss Cooperative 506 
Program. Ya.F. is also supported by the Takeda Science Foundation. Shu.K. is 507 
supported by Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for 508 
Scientific Research on Innovative Areas 26112701, Kato Memorial Bioscience 509 
Foundation and The YASUDA Medical Foundation. 510 
 511 
AUTHOR CONTRIBUTIONS  512 
Shu.K. designed experiments and generated most of the data. K.I. performed qRT-513 
PCR experiments and metabolic analyses. H.K. and Sho.K. designed and analysed the 514 
cell competition mouse model. S.I., H.Y., Y.Y., To.Ma., H.W., Ri.E., A.N., I.K., S.T., 515 
R.N. and Ta. M. assisted experiments. M.K., A.S., Ry.E., S.H., S.Y., J.K. and M.Is. 516 
performed time-lapse experiments. T.K. performed electron microscopic analyses. 517 
J.M.N., Ya.O., Yo.F. and Yu.O. performed FRET analysis. H.I., To.So. and M.R.D. 518 
assisted metabolic analyses. Y. S., M.O., J.M. and T.Sa. assisted ex vivo and in vivo 519 
experiments. Ta.S., To.Mo., M.Im. and E.N. assisted iGT experiments. Ya.F. 520 
conceived and designed the study. The manuscript was written by Shu.K. and Ya.F. 521 
with assistance from the other authors. 522 
 523 
 22
COMPETING FINANCIAL INTERESTS  524 
The authors declare no competing financial interests.  525 
 526 
527 
 23
Figure legends 528 
 529 
Figure 1. Mitochondrial membrane potential is diminished in RasV12-530 
transformed cells that are surrounded by normal epithelial cells. (a-g) 531 
Incorporation of TMRM or mitoSOX in RasV12-transformed cells surrounded by 532 
normal cells. (a, d, e) Confocal images of MDCK-pTR GFP-RasV12 or MDCK-pTR 533 
GFP cells mixed with normal MDCK cells, or cultured alone. Cells were loaded with 534 
50 nM TMRM (red) (a, b, d) or 5 μM MitoSOX (red) (e, f). Arrows indicate RasV12-535 
transformed cells showing diminished TMRM (a) or mitoSOX (e) fluorescence. (b, f) 536 
Quantification of the fluorescence intensity of TMRM (b) or mitoSOX (f). Data are 537 
mean ± s.e.m.. Values are expressed as a ratio relative to MDCK. *P<0.001, unpaired 538 
two-tailed t-test; n=92, 24, 53 and 60 cells (b) or n=52, 45 and 31 cells (f) pooled 539 
from three independent experiments. (c) CMTPX incorporation in RasV12-540 
transformed cells. MDCK-pTR GFP-RasV12 cells were mixed with normal MDCK 541 
cells or cultured alone, and loaded with 5 μM CMTPX (red). (d) Confocal images of 542 
xz sections of apically extruding or extruded RasV12-transformed cells surrounded by 543 
normal cells and of RasV12-transformed cells cultured alone. (g) The measurement of 544 
fluorescence intensity of TMRM or MitoSOX using image cytometer in MDCK-pTR 545 
GFP-RasV12 cells mixed with normal MDCK cells or cultured alone. Cells were 546 
loaded with 50 nM TMRM or 5 μM MitoSOX.(h) Immunofluorescence images of 547 
Tom20. MDCK-pTR GFP-RasV12 cells were mixed with normal MDCK cells or 548 
cultured alone, and were stained with Hoechst 33342 (blue) and anti-Tom20 antibody 549 
(red). Scale bars, 10 μm (a, c-e, h). Statistics source data for b, f are provided in 550 
Supplementary Table 2. 551 
 552 
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Figure 2. Warburg effect-like metabolic changes in RasV12-transformed cells 553 
that are surrounded by normal cells. (a) 2-NBDG incorporation in myc-RasV12 554 
cells. MDCK-pTRE3G myc-RasV12 cells co-cultured with MDCK cells or cultured 555 
alone were loaded with 100 μM 2-NBDG. (b) Quantification of the fluorescence 556 
intensity of 2-NBDG. Data are mean ± s.e.m.. Values are expressed as a ratio relative 557 
to MDCK. *P<0.001, unpaired two-tailed t-test; n=66, 66 and 48 cells pooled from 558 
three independent experiments. (c) Accumulation of LDHA in RasV12-transformed 559 
cells surrounded by normal cells. MDCK-pTR GFP-RasV12 cells were mixed with 560 
normal MDCK cells or cultured alone, and were stained with Hoechst 33342 (blue), 561 
anti-LDHA antibody (red) and Alexa-Fluor-647-conjugated phalloidin (white). Scale 562 
bars, 10 μm (a, c). (d) Quantification of the percentage of LDHA-enriched RasV12-563 
transformed cells. Data are mean ± s.e.m.. *P<0.05, unpaired two-tailed t-test; n= two 564 
independent experiments. (e) The measurement of fluorescence intensity of LDHA 565 
using image cytometer in MDCK-pTR GFP-RasV12 cells mixed with normal MDCK 566 
cells or cultured alone. Cells were stained with Hoechst 33342 and anti-LDHA 567 
antibody. (f) Lactate concentration in the conditioned medium at 12-24 h after 568 
tetracycline addition. The mean values of the indicated single cultures are also shown 569 
as the gray bars. Data are mean ± s.e.m.. *P<0.001, unpaired two-tailed t-test; n= five 570 
independent experiments for MDCK alone, RasV12 alone and MDCK:RasV12=1:1, 571 
two independent experiments for RasV12 shLDHA1 alone and MDCK:RasV12 572 
shLDHA1=1:1 and three independent experiments for RasV12 shLDHA2 alone and 573 
MDCK:RasV12 shLDHA2=1:1. Statistics source data for b, d, f are provided in 574 
Supplementary Table 2. 575 
 576 
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Figure 3. PDK4 plays a crucial role in the decreased mitochondrial membrane 577 
potential and apical extrusion of RasV12-transformed cells surrounded by 578 
normal cells. (a) Quantitative RT-PCR analysis of various metabolic enzymes in 579 
RasV12-transformed cells surrounded by normal cells. MDCK-pTR GFP-RasV12 580 
cells were co-cultured with normal MDCK cells or cultured alone. GFP-positive 581 
RasV12 cells were selectively collected by FACS sorting and subjected to qPCR 582 
analysis. Values are shown as fold change in RasV12 cells surrounded by normal cells 583 
relative to RasV12 cells cultured alone. Data are mean ± s.e.m.. *P<0.05, unpaired 584 
two-tailed t-test; n= three or four independent experiments. (b) Immunofluorescence 585 
images of phosphorylated PDH. MDCK-pTR GFP-RasV12 were mixed with normal 586 
MDCK cells or cultured alone, and were stained with Hoechst 33342 (blue) and anti-587 
p-PDH antibody (red). (c) Quantification of the fluorescence intensity of p-PDH. Data 588 
are mean ± s.e.m.. Values are expressed as a ratio relative to MDCK. *P<0.005, 589 
unpaired two-tailed t-test; n=93, 147 and 89 cells pooled from three independent 590 
experiments. (d) The measurement of fluorescence intensity of p-PDH using image 591 
cytometer in MDCK-pTR GFP-RasV12 cells mixed with normal MDCK cells or 592 
cultured alone. Cells were stained with Hoechst 33342 and anti-p-PDH antibody. (e-i) 593 
Effect of PDK4-knockdown on TMRM incorporation (f, g) or apical extrusion (h, i) 594 
of RasV12 cells surrounded by normal cells. (e) Establishment of MDCK-pTR GFP-595 
RasV12 cells stably expressing PDK4-shRNA1 or -shRNA2. Knockdown of PDK4 596 
was confirmed by quantitative RT-PCR. Data are mean ± s.e.m.. *P<0.01, unpaired 597 
two-tailed t-test; n= three independent experiments. (f) MDCK-pTR GFP-RasV12 598 
PDK4-shRNA1 or -shRNA2 cells were mixed with normal MDCK cells and loaded 599 
with TMRM. (g) Quantification of the fluorescence intensity of TMRM. Data are 600 
mean ± s.e.m.. Values are expressed as a ratio relative to MDCK. *P<0.001, unpaired 601 
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two-tailed t-test; n= 92, 92, 97 and 102 cells pooled from three independent 602 
experiments. (h) Immunofluorescence images of xz sections of MDCK-pTR GFP-603 
RasV12 PDK4-shRNA1 or -shRNA2 cells surrounded by normal MDCK cells. 604 
Arrowheads indicate the basal protrusion. Scale bars, 10 μm (b, f, h). (i) 605 
Quantification of the apical extrusion and basal protrusion formation. Data are mean ± 606 
s.e.m.. *P<0.05, unpaired two-tailed t-test; n=three independent experiments. 607 
Statistics source data for a, c, e, g, i are provided in Supplementary Table 2. 608 
 609 
Figure 4. DCA treatment abolishes the Warburg effect-like metabolic changes 610 
and suppresses apical extrusion of RasV12-transformed cells. (a) Effect of DCA 611 
on p-PDH or LDHA. MDCK-pTR GFP-RasV12 cells were mixed with normal 612 
MDCK cells in the absence or presence of 25 mM DCA. Cells were stained with 613 
Hoechst 33342 (blue) and anti-p-PDH or anti-LDHA antibody (red). (b-e) Effect of 614 
DCA on TMRM incorporation (b, c) or apical extrusion (d, e) of RasV12-transformed 615 
cells. (b) MDCK-pTR GFP-RasV12 cells were co-cultured with normal MDCK cells 616 
in the absence or presence of 25 mM DCA and incubated with 50 nM TMRM. (c) 617 
Quantification of the fluorescence intensity of TMRM. Data are mean ± s.e.m.. 618 
Values are expressed as a ratio relative to MDCK (-DCA). *P<0.001, unpaired two-619 
tailed t-test; n= 84, 82, 98 and 90 cells pooled from three independent experiments. 620 
(d) Immunofluorescence images of xz sections of MDCK-pTR GFP-RasV12 cells 621 
surrounded by normal MDCK cells in the absence or presence of DCA. An arrowhead 622 
indicates the basal protrusion. Scale bars, 10 μm (a, b, d). (e) Quantification of the 623 
apical extrusion and basal protrusion formation of RasV12 cells in the absence or 624 
presence of DCA. Data are mean ± s.e.m.. *P<0.05, unpaired two-tailed t-test; 625 
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n=three independent experiments. Statistics source data for c, e are provided in 626 
Supplementary Table 2. 627 
 628 
Figure 5. EDAC and EPLIN act upstream of the Warburg effect-like metabolic 629 
changes in RasV12 cells surrounded by normal cells. (a) TMRM incorporation in 630 
EPLIN-knockdown RasV12-transformed cells. MDCK-pTR GFP-RasV12 cells or 631 
MDCK-pTR GFP-RasV12 EPLIN-shRNA1 cells were co-cultured with normal 632 
MDCK cells and loaded with 50 nM TMRM. (b) Quantification of the fluorescence 633 
intensity of TMRM. Data are mean ± s.e.m.. Values are expressed as a ratio relative to 634 
MDCK. *P<0.001, unpaired two-tailed t-test; n=64, 21 and 45 cells pooled from two 635 
independent experiments. (c) Effect of EPLIN-knockdown on the mRNA level of 636 
PDK4 in RasV12 cells surrounded by normal cells. MDCK-pTR GFP-RasV12 cells 637 
or MDCK-pTR GFP-RasV12 EPLIN-shRNA1 cells were co-cultured with normal 638 
MDCK cells or cultured alone. GFP-positive RasV12 cells were selectively collected 639 
by FACS sorting and subjected to qPCR analysis. Values are shown as fold change in 640 
RasV12 cells surrounded by normal cells relative to RasV12 cells cultured alone. 641 
Data are mean ± s.e.m.. *P<0.05, unpaired two-tailed t-test; n= three independent 642 
experiments. (d) Effect of EPLIN-knockdown on PDH phosphorylation or LDHA 643 
accumulation. MDCK-pTR GFP-RasV12 cells or MDCK-pTR GFP-RasV12 EPLIN-644 
shRNA1 cells were co-cultured with normal MDCK cells. Cells were stained with 645 
Hoechst 33342 (blue) and anti-p-PDH or anti-LDHA antibody (red). (e) TMRM 646 
incorporation in RasV12-transformed cells surrounded by Filamin-knockdown cells. 647 
MDCK-pTR GFP-RasV12 cells were co-cultured with MDCK cells or MDCK-pTR 648 
Filamin-shRNA1 cells, and loaded with 50 nM TMRM. (f) Quantification of the 649 
fluorescence intensity of TMRM. Data are mean ± s.e.m.. Values are expressed as a 650 
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ratio relative to MDCK. *P<0.001, unpaired two-tailed t-test; n= 50, 41 and 42 cells 651 
pooled from three independent experiments. (g) Effect of Filamin-knockdown in the 652 
surrounding normal cells on PDH phosphorylation or LDHA accumulation in 653 
RasV12-transformed cells. MDCK-pTR GFP-RasV12 cells were co-cultured with 654 
MDCK-pTR Filamin-shRNA1 cells. Cells were stained with Hoechst 33342 (blue) 655 
and anti-p-PDH or anti-LDHA antibody (red). Scale bars, 10 μm (a, d, e, g). Statistics 656 
source data for b, c, f are provided in Supplementary Table 2. 657 
 658 
Figure 6. FRET analyses for intracellular glucose. (a) Schematics for Glucose-659 
FRET. (b) Glucose-FRET images. MDCK-pTRE3G myc-RasV12 cell lines stably 660 
expressing FLII12Pglu-700μδ6 (RasV12 Glu-FRET No. 1 or No. 2) were co-cultured 661 
with MDCK cells or cultured alone with doxycycline for 16 h and then analysed by 662 
dual-emission fluorescence microscopy. FRET/CFP ratio images were generated to 663 
represent FRET efficiency. Scale bars, 10 μm. (c) Quantification of Glucose-FRET 664 
efficiency (FRET/CFP). The box plots represent values from the 25th (bottom) to the 665 
75th (top) percentiles, with the median as the horizontal line. *P<0.001, unpaired two-666 
tailed t-test; n=40, 61, 41 and 68 cells pooled from three independent experiments. 667 
Statistics source data for c are provided in Supplementary Table 2. 668 
 669 
Figure 7. PDK-mediated mitochondrial dysfunction induces apical elimination of 670 
RasV12-transformed cells ex vivo. (a) Strategy for the establishment of the cell 671 
competition mouse model. (b) Immunofluorescence images of intestinal organoids 672 
from Villin-CreERT2;LSL-RasV12-IRES-eGFP or ;LSL-eGFP mice after treatment of 673 
100 nM tamoxifen. The areas in the white boxes are shown at higher magnification in 674 
the lower panels. ‘Extruding’; with their nucleus apically shifted, but still attached to 675 
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the basement membrane. ‘Extruded’; completely detached from the basement 676 
membrane and translocated into the apical lumen. Data are mean ± s.e.m.. *P<0.001 677 
for extruded + extruding between RasV12-GFP- and GFP-expressing cells, unpaired 678 
two-tailed t-test; n=three independent experiments. (c) Immunofluorescence images 679 
of intestinal organoids from villin-CreERT2;LSL-RasV12-IRES-eGFP mice at 24 h after 680 
1 μM tamoxifen treatment. The arrow and arrowhead indicate an apically extruding 681 
RasV12 cell and the cluster of several RasV12 cells that are not extruded and remain 682 
within the epithelium, respectively. For quantification, the clusters are categorized by 683 
the number of RasV12 cells present in each cluster. Data are mean ± s.e.m.. n=three 684 
independent experiments. (d-f) TMRM incorporation (d, e) or immunofluorescence of 685 
p-PDH (f) in intestinal organoids from villin-CreERT2;LSL-RasV12-IRES-eGFP or 686 
;LSL-eGFP mice at 24 h after tamoxifen treatment. Arrows indicate RasV12-687 
transformed cells with elevated PDH phosphorylation. (e) Quantification of the 688 
fluorescence intensity of TMRM. Data are mean ± s.e.m.. *P<0.001, unpaired two-689 
tailed t-test; n=71, 37, 30 and 28 cells pooled from three independent experiments. (g, 690 
h) Effect of DCA on apical extrusion ex vivo. (g) Intestinal organoids from villin-691 
CreERT2;LSL-RasV12-IRES-eGFP mice were treated with 100 nM tamoxifen and 692 
cultured for 24 h in the absence or presence of DCA. Asterisks in the images indicate 693 
mucin-rich, autofluorescent materials in the apical lumen (b-d, f, g). Ba and Ap stand 694 
for the basal and apical side, respectively (b-d, f, g). Scale bars, 10 μm (b-d, f, g). (h) 695 
Quantification of the effect of DCA on apical extrusion ex vivo. Data are mean ± 696 
s.e.m.. *P<0.005, unpaired two-tailed t-test; n=two or three independent experiments. 697 
Statistics source data for b, c, e, h are provided in Supplementary Table 2. 698 
 699 
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Figure 8. PDK-mediated mitochondrial dysfunction induces apical elimination of 700 
RasV12-transformed cells in vivo. (a) Immunofluorescence images of intestinal villi 701 
from Villin-CreERT2;LSL-eGFP or ;LSL-RasV12-IRES-eGFP mice after tamoxifen 702 
injection. Note that apicobasal polarity is apparently reversed between ex vivo and in 703 
vivo. (b) ‘Not extruded’; remaining within the epithelium. ‘Apical extruding’; with 704 
their nucleus apically shifted, but still attached to the basement membrane. ‘Apical 705 
extruded’; completely detached from the basement membrane and translocated into 706 
the apical lumen. An arrow indicates ‘Basal extruding’; basally delaminated beneath 707 
the basement membrane. (c) Quantification of the apical and basal extrusion. Data are 708 
mean ± s.e.m.. *P<0.05 for extruded + extruding between GFP- and RasV12-GFP-709 
expressing cells, unpaired two-tailed t-test; n=two independent experiments. (d) 710 
Intravital two-photon imaging of the small intestine of Villin-CreERT2;LSL-RasV12-711 
IRES-eGFP mice. The arrowhead indicates an apically extruding cell. Scale bar, 50 712 
μm. (e) villin-CreERT2;LSL-RasV12-IRES-eGFP or ;LSL-eGFP mice pre-treated with 713 
or without DCA were injected with tamoxifen and sacrificed 3 days later while DCA 714 
was continuously administrated during this period. Arrowheads indicate apically 715 
extruding or extruded cells. (f) Quantification of the effect of DCA on apical 716 
extrusion in vivo. Data are mean ± s.e.m.. *P<0.01, unpaired two-tailed t-test; n=two 717 
or three independent experiments. (g) An iGT operated mouse. The dotted line 718 
indicates the iGT-operated intestinal region. (h) Immunofluorescence images of iGT-719 
operated intestinal villi with or without Cy3-siRNA-containing HVJ-E. Scale bars, 720 
100 μm. (i) Effect of scramble- or PDK4-siRNA on expression of PDK4 in the iGT-721 
operated intestinal epithelium. PDK4-knockdown is confirmed by western blotting. 722 
(j) Immunofluorescence images of intestinal villi from the non iGT-operated region 723 
and scramble- or PDK4-siRNA transfected region at 3 days after tamoxifen injection. 724 
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Arrows indicate apically extruding or extruded cells. Scale bars, 10 μm (a, b, e, j). (k) 725 
Quantification of the apical and basal extrusion of RasV12-transformed cells. Data are 726 
mean ± s.e.m.. *P<0.01, unpaired two-tailed t-test; n= three independent experiments. 727 
For Fig. 8i, an unprocessed original scan of immunoblotting is also shown in 728 
Supplementary Fig. 9. Statistics source data for c, f, k are provided in Supplementary 729 
Table 2. 730 
 731 
 732 
 1
METHODS 1 
Antibodies, plasmids and materials 2 
The following antibodies were used in this study; goat anti-LDHA (sc-27230), mouse 3 
anti-Tom20 (sc-17764 clone F10) and mouse anti-EPLIN (sc-136399 clone 20) 4 
antibodies from Santa Cruz Biotechnology, mouse anti-myc (05-724 clone 4A6) and 5 
mouse anti-β-actin (MAB1501R clone C4) antibodies from Millipore, rabbit 6 
anti-phospho-PDH antibody (AP1062) from Calbiochem, mouse anti-PDH (ab110330 7 
clone 9H9AF5) and chicken anti-GFP (ab13970) antibodies from Abcam, mouse 8 
anti-E-cadherin antibody (610181 clone 36) from BD Transduction and rabbit 9 
anti-PDK4 antibody (AP7041B) from ABGENT. Alexa-Fluor-568- and 10 
-647-conjugated phalloidin (Life Technologies) were used at 1.0 U ml−1. 11 
Alexa-Fluor-568- and -647-conjugated secondary antibodies were from Life 12 
Technologies. Hoechst 33342 (Life Technologies) was used at a dilution of 1:5,000. 13 
TMRM, mitoSOX, MitoTracker Green and 2-NBDG 14 
(2-deoxy-2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-D-glucose) were obtained from 15 
Molecular Probes. The following inhibitors, Radicicol (10 μM), (S)-(-)-blebbistatin 16 
 2
(30 μM), KT5720 (4 μM), 3-MA (10 mM), Y27632 (20 μM) and Chrysin (100  μM) 17 
were from Calbiochem. L-NAME (300 μM) was from Santa Cruz, and Cytochalasin D 18 
(4 μM), NAC (5 mM), 2-DG (25 mM) and DCA (25 mM except for Fig. 7g, h and 19 
Supplementary Fig. 7c, d where 50 mM was used) were from Sigma-Aldrich. 20 
 21 
Cell culture 22 
MDCK cell lines were used in this study. Parental MDCK cell is the gift from Walter 23 
Birchmeier. The cell line was not found in the database of commonly misidentified cell 24 
lines that is maintained by ICLAC and NCBI Biosample. Mycoplasma contamination is 25 
regularly tested for all cell lines in use using a commercially available kit (MycoAlert, 26 
Lonza). The cell lines were not further authenticated. MDCK, MDCK-pTR 27 
GFP-RasV12, MDCK-pTR cSrcY527F-GFP, MDCK-pTR Scribble-shRNA, 28 
MDCK-pTR GFP-RasV12 EPLIN-shRNA and MDCK-pTR Filamin A-shRNA cells 29 
were cultured as previously described10, 14-16. To establish MDCK -pTRE3G 30 
myc-RasV12 cells, cDNA of myc-H-RasV12 was cloned into BamHI/EcoRI sites of 31 
pPB-TRE3G-MCS-CEH-rtTA3-IP, which was constructed by introducing the TRE3G 32 
 3
promoter with cloning sites, insulator and rtTA3-expressing elements into a 33 
PiggyBac-based vector (SBI). MDCK cells were then transfected with pPB-TRE3G 34 
myc-RasV12 by nucleofection (nucleofector 2b Kit L, Lonza), followed by selection in 35 
medium containing 5 μg ml-1 blasticidin (Invitrogen). MDCK-pTRE3G myc-RasV12 36 
cells stably expressing FLII12Pglu-700μδ649 were established by co-transfecting MDCK 37 
cells with pPB-TRE3G myc-RasV12 and pPB-FLII12Pglu-700μδ6 , followed by the 38 
same selection method as above. To establish MDCK-pTR GFP-RasV12 cells stably 39 
expressing PDK4-shRNA, LDHA-shRNA or Luciferase-shRNA, or MDCK cells stably 40 
expressing PDH-shRNA or Luciferase-shRNA in a tetracycline-inducible manner, each 41 
shRNA sequences were cloned into the BglII and XhoI site of pSUPER.neo+gfp (for the 42 
former three shRNAs) or pSUPERIOR.neo+gfp (for the latter two 43 
shRNAs)(Oligoengine). Sequences of shRNAs are listed in Supplementary Table 1. For 44 
tetracycline-inducible MDCK cell lines, 2 μg ml-1 of tetracycline (Sigma-Aldrich) was 45 
used to induce expression of proteins or shRNAs except for MDCK-pTRE3G 46 
myc-RasV12 cells for which 1 μg ml-1 of doxycycline (Sigma-Aldrich) was used. 47 
MDCK-pTR Filamin A-shRNA cells were incubated with tetracycline for 48 h to 48 
 4
induce sufficient knockdown prior to co-incubation with MDCK-pTR GFP-RasV12 49 
cells. For immunofluorescence, cells were plated onto collagen gel-coated coverslips. 50 
Type-I collagen (Cellmatrix Type I-A) was obtained from Nitta Gelatin and was 51 
neutralized on ice to a final concentration of 2 mg ml–1 according to the manufacturer’s 52 
instructions. The CellTracker dyes, CMTPX (red dye), CMFDA (green dye) and 53 
CMAC (blue dye) (Life Technologies) were used according to the manufacturer’s 54 
instructions. 55 
 56 
CRISPR/Cas9-based generation of PDK4 knockout cells 57 
Guide sequences of PDK4 sgRNA1 and 2 targeting canis PDK4 were designed on the 58 
exon 1 and 9, respectively, as described previously50. PDK4 sgRNA sequences (PDK4 59 
sgRNA1, 5’-GCTTCGTGATGCGCAGCGC-3’; PDK4 sgRNA2, 60 
5’-ACGGCACCAACGCCTGTGA-3’) were introduced into the 61 
pCDH-EF1-Hygro-sgRNA vector51 using primers listed in Supplementary Table 1. 62 
First, MDCK cells were infected with lentivirus carrying pCW-Cas9 as described51, and 63 
were cultured in the 500 ng ml-1 puromycin-containing medium. The 64 
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tetracycline-inducible MDCK-Cas9 cells were transfected with the pCDH-EF1-PDK4 65 
sgRNA1 and 2 by nucleofection, followed by selection in medium containing 200 μg 66 
ml-1 of Hygromycin and subjected to limiting dilution. Indels on the PDK4 exons in 67 
each monoclone were analysed by direct sequencing using primers listed in 68 
Supplementary Table 1. To generate PDK4-deleted cells carrying doxycycline-inducible 69 
GFP-RasV12, pPB-TRE3G GFP-RasV12 was introduced into the PDK4-deleted cells 70 
by nucleofection and antibiotics selection. In addition to the PDK4-/- MDCK-pTRE3G 71 
GFP-RasV12 cells, we generated PDK4+/+ MDCK-pTRE3G GFP-RasV12 cells as a 72 
control cell line. 73 
 74 
Mice 75 
All animal experiments were conducted under the guidelines by the Animal Care 76 
Committee of Hokkaido University. The animal protocols were reviewed and approved 77 
by the Hokkaido University Animal Care Committee (Approval number:12-0116). We 78 
used 6-10 weeks old C57BL/6 mice of either sex. To establish 79 
DNMT1-CAG-loxP-STOP-loxP-HRasV12-IRES-eGFP knock-in mice, the genomic 80 
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fragments of DNA methyltransferase 1 (DNMT1) locus, the loxP-flanked stop and 81 
neomycin resistance cassette, cDNA encoding HRasV12 plus frt-flanked IRES-eGFP and 82 
diphtheria toxin subunit A gene were inserted into the targeting vector. The resulting 83 
plasmid DNA was linearized and electrophoretically transfected into IB10 ES cells. 84 
Recombinant alleles were verified by Southern blot analysis. The independent clones 85 
were each injected into blastcysts of C57BL/6 mice and were successfully transmitted 86 
through the germ-line, and DNMT1-CAG-loxP-STOP-loxP-HRasV12-IRES-eGFP mice 87 
(acc. no. CDB0706K: http://www2.clst.riken.jp/arg/mutant%20mice%20list.html) were 88 
thus established. Villin-CreERT2 mice52 were crossed with 89 
DNMT1-CAG-loxP-STOP-loxP-HRasV12-IRES-eGFP mice or 90 
CAG-loxP-STOP-loxP-eGFP mice53 to create Villin-RasV12-GFP or Villin-GFP mice 91 
respectively. Mice heterozygous for each transgene were used for experiments. For PCR 92 
genotyping of mice, primers listed in Supplementary Table 1 were used. The expected 93 
sizes of PCR products were 220 bp, 403 bp and 390 bp for Villin-CreERT2, 94 
DNMT1-CAG-loxP-STOP-loxP-HRasV12-IRES-eGFP and 95 
CAG-loxP-STOP-loxP-eGFP mice, respectively. For culturing intestinal organoids, 96 
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isolated crypts from the mouse small intestine were entrapped in Matrigel (Corning) and 97 
plated in a non-coated 35-mm glass bottom dish as previously described36. The crypts 98 
embedded in Matrigel were covered with Advanced DMEM/F12 supplemented with N2 99 
(Invitrogen), B27 (Invitrogen), 50 ng ml–1 EGF (Peprotech), 100 ng ml–1 Noggin 100 
(Peprotech), 1.25 mM N-Acetylcystein (Sigma-Aldrich) and R-spondin conditioned 101 
medium collected from 293T-HA-Rspol-Fc cells kindly provided by Dr. Calvin Kuo 102 
(Stanford University). After 96 h culture, organoids were incubated with tamoxifen 103 
(Sigma) for 24 h to induce transgenes. Subsequently, tamoxifen was washed out, and 104 
organoids were cultured for the indicated times for analyses. For in vivo experiments, 105 
6-10 weeks old Villin-RasV12-GFP or Villin-GFP mice were given a single 106 
intraperitoneal injection of 2 mg of tamoxifen in corn oil (Sigma), and were then 107 
sacrificed at 2, 3, 5 or 7 days after Cre activation. To examine the effect of DCA, the 108 
mice were first pretreated with 5.0 g l–1 DCA in the drinking water for 2 weeks. 109 
Subsequently, the mice were injected intraperitoneally with 2.0 mg of tamoxifen and 110 
sacrificed 3 days later while DCA was continuously administrated during this period. 111 
The iGT (intestine-specific gene transfer) experiments were performed as previously 112 
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described37. Briefly, 3-5 cm regions of small intestine drawn out from the peritoneal 113 
cavity were tied with nylon string. 300 μl of the mucus removing solution (20 mM 114 
DTT, 0.05% Tween-20 in PBS) was injected into the intestinal lumen for 15 min, 115 
removed and incubated with the same solution for 10 min. After washing with PBS 116 
three times by pipetting, 300 μl of the transfection solution containing Cy3-labelled 117 
siRNA and HVJ-E (haemagglutinating virus of Japan envelope) was injected, and the 118 
mice were left for 1 h. The sequences of Scramble- and PDK4-siRNA are listed in 119 
Supplementary Table 1. 2.0 mg of tamoxifen was injected into the peritoneal cavity 120 
when the wound was sutured. The mice were sacrificed for the analysis after 3 days of 121 
iGT. 122 
 123 
Immunofluorescence and western blotting 124 
For immunofluorescence, MDCK-pTR GFP-RasV12, MDCK-pTR cSrcY527F-GFP, 125 
MDCK-pTR Scribble-shRNA, MDCK-pTRE3G myc-RasV12, MDCK-pTR 126 
GFP-RasV12 PDK4-shRNA, MDCK-pTRE3G GFP-RasV12 PDK4-sgRNA, 127 
MDCK-pTR PDH-shRNA, MDCK-pTR GFP-RasV12 EPLIN-shRNA, MDCK-pTR 128 
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GFP-RasV12 LDHA-shRNA or MDCK-pTR GFP-RasV12 Luciferase-shRNA cells 129 
were mixed with MDCK, MDCK-pTR Filamin A-shRNA or MDCK-pTR 130 
Luciferase-shRNA cells at a ratio of 1:50 and plated onto collagen-coated coverslips as 131 
previously described10. The mixture of cells was incubated for 8-12 h, followed by 132 
tetracycline or doxycycline treatment for 16 h, except for analyses of apical extrusions 133 
that were examined after 24 h of tetracycline or doxycycline addition. Cells were fixed 134 
with 4% paraformaldehyde (PFA) in PBS and permeabilised as previously described11. 135 
All primary antibodies were used at 1:100, and all secondary antibodies were used at 136 
1:200. To monitor the mitochondrial activity or superoxide production, cells were 137 
loaded with 50 nM TMRM or 5 μM MitoSOX respectively for 30 min and subjected to 138 
microscopic observation or quantitatively analysed by CellInsightTM image cytometer 139 
(Thermo Fisher Scientific). As to TMRM, we have thoroughly checked and optimized 140 
the experimental conditions. After titration of TMRM concentration, we chose 50 nM 141 
that provides clear and sufficient fluorescence intensity. By checking the effect of 142 
oligomycin and FCCP, we confirmed that the experimental condition is under the 143 
non-quenching mode using 50 nM TMRM54. We also confirmed that 2 μg ml-1 144 
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tetracycline did not affect TMRM fluorescence. The ratiometric images of TMRM and 145 
MitoTracker Green were obtained by incubating cells with 200 nM MitoTracker Green 146 
for 2 h, briefly washed, and then loaded with 50 nM TMRM. The 2-NBDG uptake was 147 
examined by incubating cells with glucose-free DMEM for 2 h followed by addition of 148 
100 μM 2-NBDG for 30 min. For immunofluorescence using intestinal organoids, cells 149 
grown in matrigels were incubated with Cell Recovery Solution (Corning) for 8 min 150 
before fixation with 4% PFA. After fixation, cells were permeabilised in 0.5% Triton 151 
X-100/PBS for 1 h and blocked in 1% BSA/PBS for 1 h. For immunohistochemical 152 
examinations of the small intestine, the tissues were isolated and fixed in 4% PFA, 153 
dehydrated, and embedded in paraffin. Microsections of each specimen were placed on 154 
glass slides, de-paraffinized and processed for immunostaining. The iGT-operated small 155 
intestine was embedded in OCT compound (Tissue-Tek), and frozen sections (10 μm) 156 
were cut on a cryostat. Immunofluorescence images were analysed by the Olympus 157 
FV1000 or FV1200 system and Olympus FV10-ASW software. Images were quantified 158 
by the MetaMorph software (Molecular Devices). Western blotting was performed as 159 
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previously described55. Primary antibodies were used at 1:1,000. The western blotting 160 
data were analysed using ImageQuantTM LAS4010 (GE Healthcare).  161 
 162 
FRET analysis 163 
Glucose-FRET experiments were performed as previously described56. In brief, 164 
MDCK-pTRE3G myc-RasV12 cells stably expressing FLII12Pglu-700μδ6 were 165 
co-cultured with MDCK cells at a ratio of 1:50 or cultured alone on a collagen gel in 166 
35-mm-diameter, glass-bottom dishes (Matsunami Glass). At 16 h after doxycycline 167 
addition, a differential interference contrast (DIC) image and CFP and FRET 168 
fluorescence images were recorded. FRET efficiency was calculated as a quotient of 169 
background-subtracted FRET and CFP images and is presented in an intensity-modified 170 
display mode with the MetaMorph software. In the intensity-modified display mode, 171 
eight colors from red to blue are used to represent the FRET efficiency. To evaluate 172 
ATP level, MDCK-pTRE3G myc-RasV12 cells were transiently transfected with 173 
ATeam probe57, stained with CMTPX, and were co-cultured with MDCK cells at ratio 174 
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of 1:50 or cultured alone on a collagen gel in 35-mm-diameter, glass-bottom dishes. At 175 
16 h after doxycycline addition, FRET efficiency was examined as described above.  176 
 177 
Time-lapse microscopic observation 178 
For ex vivo time-lapse analyses, intestinal organoids grown in matrigels were incubated 179 
with 100 nM tamoxifen for 24 h to induce transgenes. Subsequently, time-lapse 180 
observation was carried out for 24 h in the medium containing no tamoxifen by the 181 
Nipkow spinning disk confocal microscopy (X-Light; Crest Optics). Fluorescence 182 
images (853 x 720 pixels, 0.975-μm resolution) were captured at an exposure of 0.25 s. 183 
Images of 42-μm depth in the z-axis were obtained at 3-μm z-steps.  184 
For intravital imaging of small intestine in living mice, mice were anesthetized with 185 
isoflurane, the small intestine was surgically exposed, and then villi were observed by 186 
using two-photon excitation microscopy. Intestinal lumen was visualized with 70-kDa 187 
tetramethylrhodamine-conjugated dextran (Sigma). Nuclei of cells were stained with 188 
intravenous injection of Hoechst33342 (Life Technologies) just before imaging. The 189 
imaging system was composed of a two-photon microscope (A1-MP; Nikon) driven by 190 
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a laser (Chameleon Vision II Ti: Sapphire; Coherent) tuned to 880 nm and an inverted 191 
microscope equipped with a 20× objective lens (Plan Fluor; N.A., 0.75; Nikon). 192 
Fluorescent signals were detected through band-pass emission filters at 525/50 nm (for 193 
GFP) and at 575/25 nm (for tetramethylrhodamine). Raw imaging data were processed 194 
using the Imaris software (Bitplane). 195 
 196 
Electron microscopy 197 
MDCK-pTR GFP-RasV12 cells were cultured alone or co-cultured with MDCK cells in 198 
collagen gel-coated, grid-imprinted plastic dishes (μ-Dish 35-mm Grid-500, Ibidi 199 
Corporation). After tetracycline treatment for 24 h, cells were fixed in 2% 200 
glutaraldehyde in HEPES buffer (30 mM HEPES, 0.1 M NaCl and 2 mM CaCl2 (pH 201 
7.4)), and fluorescence and DIC images of GFP-RasV12 cells and the surrounding cells 202 
were captured together with the underlying, numbered grid information. Cells were then 203 
post-fixed in 2% osmium tetroxide in 0.1 M imidazole (pH 7.4) and stained with 1% 204 
uranyl acetate (UA) before being dehydrated and embedded in Araldite-Epon resin 205 
(Electron Microscopy Sciences). During these procedures, GFP fluorescence was lost, 206 
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but the grid was imprinted onto the resin. Subsequently, GFP-RasV12 cells and the 2 or 207 
3 rows of surrounding MDCK cells were selected and excised, while referring to the 208 
grid information, morphology of the cells and the captured images. Ultrathin sections of 209 
the trimmed sample were poststained with UA and lead citrate, and cells were imaged 210 
with an electron microscope (JEM-1400; JEOL Corporation) operating at 80 kV. 211 
 212 
Quantitative real-time PCR 213 
MDCK-pTR GFP-RasV12 cells or 10:1 mix culture of MDCK and MDCK-pTR 214 
GFP-RasV12 cells were cultured at a density of 2x107 cells on the collagen-coated 215 
15-cm dishes (Greiner-Bio-One). After incubation with tetracycline for 16 h, 216 
GFP-positive RasV12 cells and GFP-negative MDCK cells were separated with an 217 
analytical flow cytometer. Total RNA was extracted from the isolated cells using 218 
Trizol® (Thermo Fisher Scientific) and the RNeasy Mini Kit (QIAGEN) and reverse 219 
transcribed using QuantiTect Reverse Transcription Kit (QIAGEN). GeneAce SYBR 220 
qPCR Mix (NIPPON GENE) was used to perform qPCR using the StepOneTM system 221 
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(Thermo Fisher Scientific). The primer sequences used are listed in Supplementary 222 
Table 1. We used β-actin as a reference gene to normalise data. 223 
 224 
Lactate assay 225 
For lactate assay, MDCK cells, MDCK-pTR GFP-RasV12 cells, MDCK-pTR 226 
GFP-RasV12 LDHA-shRNA cells or 1:1 mix of MDCK and MDCK-pTR GFP-RasV12 227 
or MDCK-pTR GFP-RasV12 LDHA-shRNA cells were cultured at a density of 6.5x105 228 
cells on the collagen-coated 12-well dishes (Falcon) in DMEM containing neither 229 
phenol red nor fetal calf serum. The culture medium was replaced with fresh medium at 230 
12 h after tetracycline addition and collected 12 h later. Samples were subjected to 231 
measurement of lactate concentration using Lactate Assay kit (BioVision).  232 
 233 
HIF1 reporter assay 234 
MDCK or MDCK-pTR GFP-RasV12 cells were co-transfected with pCDH/5HRE-Luc 235 
(kindly provided by Dr. Hiroshi Harada (Kyoto University)) and pRL-TK. After 24 h, 236 
cells were trypsinised, and cultured alone or co-cultured with the indicated cells (total 237 
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cell number: 3.5x105) for 8 h, followed by tetracycline treatment for 16 h. Firefly 238 
luciferase activity was measured using Dual-Lucifease Reporter assay (Promega) and 239 
normalized by Renilla luciferase activity.  240 
 241 
Statistics and reproducibility 242 
For data analyses, unpaired two-tailed Student’s t-tests were used to determine 243 
P-values. P-values less than 0.05 were considered to be significant. No statistical 244 
method was used to predetermine sample size. For animal studies, the experiments were 245 
not randomized, and the investigators were not blinded to allocation during 246 
experiments. All results were reproduced with at least two independent experiments and 247 
at least three mice of each genotype. Representative figures are shown in Fig. 1c, g, h, 248 
2e, 3d, 4a, 5d, g, 7f, 8d, h, i and Supplementary Fig. 1a-c, f, 3c-j, 4a, d, e, h-j, 5a-c, 6b, 249 
7a, b. Each experiment was repeated independently: 2 repeats (Fig. 1c, g, 2e, 3d, 8h, i 250 
and supplementary Fig. 1c, f, 3d, i, 4a, d, e, h, j, 5a, b, 7b.), 3 repeats (Fig. 1h, 4a, 5d, g, 251 
8d and supplementary Fig. 1a, b, 3c, e, f, h, j 4i, 5c, 7a.), 4 repeats (Fig. 7f and 252 
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supplementary Fig. 3g). The experiment of supplementary Fig. 6b was performed once, 253 
but homologous recombination in ES cells was confirmed by PCR.   254 
 255 
Data availability  256 
Source data for Fig. 1b, f, 2b, d, f, 3a, c, e, g, i, 4c, e, 5b, c, f, 6c, 7b, c, e, h, 8c, f, k and 257 
Supplementary Fig. 1e, h, 3l, n, 4c, g, 5f, g, i, 6c, 7d, e have been provided as 258 
Supplementary Table 2. All data supporting the findings of this study are available from 259 
the corresponding author on request. 260 
 261 
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